Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome & identification of drug resistance mutations

Genome Research

Volumn 27, Issue 4, 2017, Pages 613-625

  Brammeld, Jonathan S ^a   Petljak, Mia ^a   Martincorena, Inigo ^a   Williams, Steven P ^a   Alonso, Luz Garcia ^b   Dalmases, Alba ^c   Bellosillo, Beatriz ^c   Robles Espinoza, Carla Daniela ^d   Price, Stacey ^a   Barthorpe, Syd ^a   Tarpey, Patrick ^a   Alifrangis, Constantine ^a   Bignell, Graham ^a   Vidal, Joana ^c   Young, Jamie ^a   Stebbings, Lucy ^a   Beal, Kathryn ^a   Stratton, Michael R ^a   Saez Rodriguez, Julio ^b,e   Garnett, Mathew ^a   Montagut, Clara ^c   Iorio, Francesco ^b   McDermott, Ultan ^a   more..

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^c HOSPITAL DEL MAR   (Spain)

^d CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTL PROTEIN HOMOLOG 1; OXALIPLATIN; PANITUMUMAB; SCATTER FACTOR RECEPTOR; TRAMETINIB;

ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEMICAL MUTAGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE MUTATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; HUMAN CHROMOSOME; HUMAN GENOME; INDEL MUTATION; MICROSATELLITE INSTABILITY; NEXT GENERATION SEQUENCING; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOLOGICAL MODEL; DRUG RESISTANCE; GENETICS; MUTATION ACCUMULATION; MUTATION RATE; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; MODELS, GENETIC; MUTATION ACCUMULATION; MUTATION RATE; POINT MUTATION;

EID: 85017538728     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.213546.116     Document Type: Article

References (45)

1. Acevedo-Arozena A, Wells S, Potter P, Kelly M, Cox RD, Brown SD. 2008. ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet 9: 49-69.
2. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013a. Signatures of mutational processes in human cancer. Nature 500: 415-421.
3. Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR. 2013b. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3: 246-259.
4. Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, et al. 2015. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 21: 2157-2166.
5. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore- Bianchi A, Scala E, Cassingena A, Zecchin D, et al. 2013. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3: 658-673.
6. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
7. Bettegowda C. 2014. Detection of circulating tumor DNA in early-And latestage human malignancies. Sci Transl Med 6: 224ra24.
8. Concepcion D, Seburn KL, Wen G, Frankel WN, Hamilton BA. 2004. Mutation rate and predicted phenotypic target sizes in ethylnitrosourea-Treated mice. Genetics 168: 953-959.
9. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. 2012. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486: 537-540.
10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. 2013. Panitumumab- FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034.
11. Eberlein CA, Stetson D, Markovets AA, Al-Kadhimi KJ, Lai Z, Fisher PR, Meador CB, Spitzler P, Ichihara E, Ross SJ, et al. 2015. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 75: 2489-2500.
12. Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA. 2015. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21: 3913-3923.
13. Fisher RA. 1922. On the interpretation of χ2 from contingency tables, and the calculation of P. J R Statist Soc 85: 87-94.
14. Forsburg SL. 2001. The art and design of genetic screens: yeast. Nat Rev Genet 2: 659-668.
15. Hu X, Zhang Z. 2016. Understanding the genetic mechanisms of cancer drug resistance using genomic approaches. Trends Genet 32: 127-137.
16. Iorio F, Garcia-Alonso L, Brammeld J, Martincorena I, Wille D, McDermott U, Saez-Rodriguez J. 2016. Population-level characterization of pathway alterations with SLAPenrich dissects heterogeneity of cancer hallmark acquisition. bioRxiv doi:10.1101/077701.
17. Justice MJ. 2000. Capitalizing on large-scale mouse mutagenesis screens. Nat Rev Genet 1: 109-115.
18. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. 2011. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci 108: 7535-7540.
19. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. 2012. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4: 120ra117.
20. Kile BT, Hilton DJ. 2005. The art and design of genetic screens: mouse. Nat Rev Genet 6: 557-567.
21. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
22. Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows- Wheeler transform. Bioinformatics 26: 589-595.
23. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.
24. Long GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP, et al. 2014. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 5: 5694.
25. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. 2012. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536.
26. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, et al. 2014. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6: 224ra226.
27. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. 2012. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223.
28. Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, et al. 2016. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534: 47-54.
29. Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K, Tanimoto M. 2007. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line. Cancer Res 67: 7807-7814.
30. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et al. 2012. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci 109: E2127-E2133.
31. Patton EE, Zon LI. 2001. The art and design of genetic screens: zebrafish. Nat Rev Genet 2: 956-966.
32. Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, et al. 2015. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov 6: 147-153.
33. Shostak K, Chariot A. 2015. EGFR and NF-κB: partners in cancer. Trends Mol Med 21: 385-393.
34. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, et al. 2015. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21: 795-801.
35. St Johnston D. 2002. The art and design of genetic screens: Drosophila melanogaster. Nat Rev Genet 3: 176-188.
36. Sun L, Craiu RV, Paterson AD, Bull SB. 2006. Stratified false discovery control for large-scale hypothesis testing with application to genomewide association studies. Genet Epidemiol 30: 519-530.
37. Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al. 2015. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21: 560-562.
38. Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy DA, Monahan JE, Jones MD, et al. 2011. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71: 5255-5264.
39. Tokunaga M, Kokubu C, Maeda Y, Sese J, Horie K, Sugimoto N, Kinoshita T, Yusa K, Takeda J. 2014. Simulation and estimation of gene number in a biological pathway using almost complete saturation mutagenesis screening of haploid mouse cells. BMC Genomics 15: 1016.
40. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al. 2010. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
41. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, et al. 2014. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4: 94-109.
42. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
43. Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, et al. 2014. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4: 61-68.
44. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, et al. 2011. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86.
45. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, et al. 2011. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Design 78: 999-1005.